8 Apr 2021 08:00
RNS Number : 8127U
Remote Monitored Systems PLC
08 April 2021
8 April 2021
Remote Monitored Systems plc
("RMS" or the "Company")
MHRA Approval
The Company confirms that the Pharm 2 Farm Limited ("P2F") Pro Larva face mask (the "Pro Larva Mask") has been approved as a Class 1 medical device by the Medicines and Healthcare products Regulatory Agency ("MHRA"). As announced earlier this year, the Pro Larva Mask was self-certified to EN 14683 standards in accordance with Government Guidelines, allowing the use of the associated CE Mark. Changes in the applicable legislation on 1 January 2021 mean that from 1 January 2022, all Class 1 medical devices, which includes the Pro Larva mask, will need to be registered with the MHRA. Following the receipt of the CE Mark, P2F registered with the MHRA earlier this year and has now secured this registration for the Pro Larva Mask so that it will continue to comply with the necessary regulations.
- ENDS -
ENQUIRIES:
Remote Monitored Systems plc
Antony Legge (Executive Chairman) via IFC Advisory
SP Angel Corporate Finance LLP +44 20 3470 0470
Nominated Adviser and Joint Broker
Stuart Gledhill
Caroline Rowe
Peterhouse Capital Limited +44 20 7469 0930
Joint Broker
Lucy Williams
IFC Advisory Ltd +44 20 3934 6630
Graham Herring
Zach Cohen
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRASSFSMAEFSELL
